ARTIVION, INC.

---

source: coverage-next-full step: 01 ticker: AORT company: Artivion, Inc. date: 2026-06-15

Step 01 — Business Model Overview: Artivion, Inc. (AORT)

1. Company Identity

Artivion, Inc. (NYSE: AORT) is an aortic surgery medical device company headquartered in Kennesaw, Georgia. Formerly CryoLife, Inc. (rebranded January 2022), the company manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgery for patients with aortic disease. [S1]

The company employs approximately 1,800 people globally, with primary manufacturing and operations in Kennesaw, GA; Hechingen, Germany (JOTEC); Austin, TX (On-X); and Herzliya, Israel (Endospan/NEXUS). [S1]

---

2. Business Model Architecture

Artivion operates a product-and-service hybrid model within the medical device sector:

Revenue Streams (FY2025)

Revenue Stream	FY2025 Revenue	% of Total	YoY Growth
Aortic Stent Grafts	$159.4M	36%	+29%
On-X Mechanical Heart Valves	$101.7M	23%	+21%
Surgical Sealants (BioGlue)	$76.6M	17%	+4%
Other Medical Device Products	$8.1M	2%	-12%
Total Medical Devices	$345.8M	78%	+19%
Preservation Services	$95.5M	22%	-3%
Total Revenue	$441.3M	100%	+14%

Source: [S1] 10-K FY2025

Value Chain Position

Artivion occupies the manufactured implant and tissue processing layer in the aortic surgery supply chain:

Upstream                          Artivion                       Downstream
─────────────────────────────────────────────────────────────────────────────
Raw materials           →   Device mfg. + tissue banking   →   Distributor/direct
(polymers, metals,          JOTEC (Hechingen, DE)               Hospital/OR
 biological tissue)         On-X (Austin, TX)                   Cardiothoracic surgeon
                            Endospan (Herzliya, IL)              Vascular surgeon
                            ↓
                       Regulatory approval (FDA/CE)
                            ↓
                       Clinical education + support
                            ↓
                       Direct + distributor sales channels

Revenue model: Product revenues recognized upon delivery/transfer of title (device sale). Preservation services recognized upon shipment of processed tissue. Both are high-gross-margin models with list pricing subject to hospital purchasing organization (GPO) contracts and international tender processes.

---

3. Product Family Deep Dive

3.1 Aortic Stent Grafts (36% of revenue, fastest growing)

The stent graft portfolio targets endovascular and hybrid surgical repair of the thoracic aorta and aortic arch — a complex surgical field dominated by Medtronic, Cook Medical, and Gore in peripheral/abdominal EVAR, with very few competitors in the complex arch segment. [S3]

Key platforms:

• NEXUS: FDA PMA approved April 7, 2026 — the first branched endovascular stent graft cleared in the U.S. for aortic arch disease. Targets patients with pathology involving the aortic arch who previously required open surgery. Based on NEXUS TRIOMPHE IDE trial. [S2]
• AMDS (Aortic Multi-Segmented Device System): Hybrid prosthesis for acute Type I aortic dissection. FDA HDE granted December 2024. PMA filing underway; expected approval mid-2026. [S1]
• JOTEC Portfolio (E-vita Open NEO, E-tegra, E-liac): CE-marked European stent graft range for arch, thoracic, and iliac applications. Artivion's primary European revenue driver; limited U.S. availability pending FDA.
• Arcevo LSA: Investigational branched device for left subclavian artery. ARTIZEN IDE trial ongoing (~8/132 patients enrolled). PMA submission target ~2029. [S2]

3.2 On-X Mechanical Heart Valves (23% of revenue)

Acquired from On-X Life Technologies in January 2016. The On-X aortic valve is the only FDA-cleared mechanical heart valve with evidence supporting a reduced anticoagulation protocol (INR 1.5–2.0 vs. 2.0–3.0 standard). PROACT Xa trial data (factor Xa inhibitor anticoagulation) is driving adoption in a patient population that historically resisted mechanical valves due to warfarin burden. [S1]

3.3 BioGlue Surgical Adhesive (17% of revenue)

Protein-based surgical sealant. Artivion's oldest product. Used in aortic and cardiac reconstruction. No direct equivalent competitor; off-label usage in other cardiac applications. Growth is modest (+4% in FY2025) — largely a stable revenue stream. [S1]

3.4 Preservation Services (22% of revenue, declining)

Cardiac and vascular cryopreserved tissue (CryoValve SynerGraft, CryoPatch, CryoVein). Business is subject to donor tissue supply variability and faces secular pricing pressure. Declined 3% in FY2025 due to supply and demand factors. Management has not explicitly telegraphed exiting the segment, but capital allocation signals suggest Devices is the growth priority. [S1]

---

4. Geographic Mix

Geography	FY2025 Revenue	% of Total
North America	$221.7M	50%
EMEA	$151.4M	34%
Asia Pacific	$44.3M	10%
Latin America	$24.0M	5%
Total	$441.3M	100%

Source: [S1] 10-K FY2025

The European exposure (~34%) creates meaningful FX risk (EUR:USD) and regulatory complexity (EU MDR), but also gives Artivion early-commercialization data on JOTEC products pending U.S. approval. [S1]

---

5. Customer and Channel Structure

• Primary customers: Cardiothoracic and vascular surgeons at major cardiac surgery centers; hospital purchasing organizations (GPOs)
• Sales channels: Direct sales force (dominant in U.S. and key European markets); distributor networks in Asia Pacific and Latin America
• Reimbursement: Hospital procedures reimbursed by DRG (U.S. Medicare/Medicaid), private insurance, and national health systems (European socialized payers). Device pricing generally embedded in hospital contract / GPO pricing
• Switching costs: Moderate — surgeon training, procedural familiarity, and credentialing create meaningful inertia once a product is adopted

---

6. Transformation Narrative

The CryoLife → Artivion transformation (2016–2026) is central to the investment thesis:

Phase	Years	Key Event
Tissue-first model	Pre-2016	~$146M revenue, tissue preservation dominant
On-X acquisition	2016	+$33M revenue, mechanical valve market entry
JOTEC acquisition	2017	+$225M cost, stent graft market entry; share dilution
Endovascular buildout	2018–2021	R&D investment, Ascyrus Medical acquisition (AMDS tech)
Rebrand to Artivion	Jan 2022	Signal device-first identity
Equity raise + deleveraging	2025	Shares +13.5%, debt -$100M+
NEXUS FDA PMA	Apr 2026	Landmark U.S. approval; arch EVAR now a real revenue line
Endospan acquisition	May 2026	Full NEXUS ownership; $135M upfront + $200M contingent

---

7. Investment Thesis Linkage

The AORT thesis rests on three compounding questions:

1. Can NEXUS and AMDS drive Medical Device segment growth from ~$346M (FY2025) to management's implied $400M+ range by FY2027?
2. Will gross margins hold at 63–65% despite Endospan integration costs and tariff headwinds?
3. Does the balance sheet — re-leveraged by the Endospan acquisition — remain serviceable while FCF is thin?

Analyst consensus is constructively positive (6 Strong Buy / 1 Buy, avg target $42 vs. ~$20 current) [S4], suggesting the market is applying a large execution-risk discount. The next 18 months of NEXUS commercial adoption data will likely be the primary re-rating catalyst.

---

Source Index

• [S1] SEC 10-K FY2025 — Artivion, Inc. (filed Feb 18, 2026)
• [S2] Investor presentation research (Tavily) — NEXUS approval, AMDS, pipeline
• [S3] Industry competitive landscape file — industry/competitive_landscape.md
• [S4] Consensus file — other/consensus.md

---

Thesis Tracker Update: Business model confirmed — aortic device platform in active commercial ramp. Preservation Services is a declining cash flow contributor. NEXUS/AMDS are the critical organic growth drivers. Endospan adds both opportunity (complete arch portfolio) and risk (re-leverage).

---

source: coverage-next-full step: 04 ticker: AORT company: Artivion, Inc. date: 2026-06-15

Step 04 — Financial Snapshot & Quality: Artivion, Inc. (AORT)

1. Income Statement Quality Analysis

Revenue Recognition

Artivion recognizes product revenue upon delivery/transfer of title to the customer, following ASC 606. Preservation services revenue recognized upon tissue shipment. No material contingent revenue arrangements noted. Revenue recognition appears conservative and appropriate for the business model. [S1]

Gross Margin Stability

Year	Revenue	Gross Profit	Gross Margin
FY2019	$276.2M	$183.0M	66.3%
FY2020	$253.2M	$167.8M	66.3%
FY2021	$298.8M	$197.5M	66.1%
FY2022	$313.8M	$202.5M	64.5%
FY2023	$354.0M	$229.2M	64.7%
FY2024	$388.5M	$248.8M	64.0%
FY2025	$441.3M	$284.2M	64.4%

Source: [S2] XBRL company facts

Observation: Gross margins have compressed ~2pp from the 66%+ range pre-2022. The shift reflects the higher COGS associated with the JOTEC stent graft portfolio (more complex manufacturing) versus legacy tissue services. Margins have stabilized in the 64–65% band over the last three years — this appears to be the new normalized range. No material revenue-recognition manipulation evident.

Operating Expense Concerns

SG&A is exceptionally high at 51.3% of revenue ($226.5M) in FY2025. This is characteristic of direct-selling medical device companies with heavy clinical support infrastructure, but it is notably above med-tech peers. R&D at 7.0% ($31M) is appropriate for an active pipeline company. [S1]

Red flag: SG&A absorbs nearly all gross profit. The operating income of $33.7M (7.6% margin) is positive but thin — and below FY2024's $38.9M despite $52.8M more revenue. This suggests SG&A grew faster than revenue in FY2025. Possible explanations: NEXUS pre-commercial launch spend, Endospan integration costs, FX headwinds in European sales force.

Non-Cash Items

Item	Magnitude	Impact on True Earnings
Amortization of acquisition intangibles	~$25M/yr (est.)	Depresses GAAP earnings but is non-cash
Stock-based compensation (SBC)	~$24M/yr (est.)	Cash dilution; management uses adj. EPS excluding SBC
Goodwill ($254M at Q1 2026)	Impairment risk on Preservation Services	Monitor for segment writedown

Adjusted EBITDA bridge: From $33.7M GAAP operating income + ~$25M D&A + ~$24M SBC + other adj = ~$82–90M adj. EBITDA (~20% margin). Management's reported adj. EBITDA of ~$89–90M in FY2025 is internally consistent. [S1]

---

2. Balance Sheet Quality

Debt and Leverage

Metric	Dec 2023	Dec 2024	Dec 2025	Q1 2026
Cash	$59M	$53M	$65M	$56M
Long-Term Debt	$307M	$314M	$215M	$215M
Net Debt	$248M	$261M	$150M	$159M
Total Assets	$792M	$789M	$885M	$883M
Stockholders' Equity	$282M	$276M	$448M	$450M

Source: [S2] XBRL

Leverage reduction was dramatic in H1 2025: Long-term debt fell from $314M (Dec 2024) to $215M (Dec 2025) — a $99M reduction driven by the secondary equity offering (shares grew from ~41.7M to ~47.2M diluted). This de-risked the balance sheet substantially. Debt/EBITDA declined from ~3.8x to ~1.7x. [S1]

Post-Endospan re-levering (May 2026): The Endospan acquisition ($135M upfront) is expected to re-lever the balance sheet. This transaction closed after the FY2025 period, so the balance sheet impact will not appear until Q2 2026. Estimated post-deal net debt: ~$290–310M, implying Debt/EBITDA back to ~2.8–3.0x on adj. EBITDA of ~$100–107M FY2026 guidance. Manageable, but a near-term constraint on financial flexibility. [S4]

Goodwill and Intangibles

• Goodwill: $254M (Q1 2026) — primarily from JOTEC ($225M acquisition cost, 2017) and On-X (2016)
• Additional intangibles (customer relationships, developed technology, trade names) not separately broken out in XBRL data but estimated at $100–150M gross based on 10-K MD&A
• Artivion's Preservation Services segment carries a portion of goodwill and intangibles — if segment performance deteriorates, a non-cash impairment write-down is possible

No goodwill impairment has been recorded in the last 3 years. [S1]

Working Capital

Metric	Dec 2024	Dec 2025
Inventory	$80M	$92M
Current Assets	$290M	$358M
Current Liabilities	$67M	$102M
Working Capital	$223M	$256M

Inventory build (+$12M YoY) likely reflects NEXUS/AMDS pre-commercial stocking. Current liabilities rose $35M — watch for accounts payable stretch if free cash flow remains constrained.

---

3. Cash Flow Quality

Metric	FY2023	FY2024	FY2025
Operating CF	$18.8M	$22.2M	$39.9M
Capital Expenditures	$9.8M	$11.2M	$39.0M
Free Cash Flow	$9.1M	$11.0M	$0.8M
FCF Margin	2.6%	2.8%	0.2%

FCF quality concern: Despite $39.9M in operating cash flow, capex tripled in FY2025 ($39.0M vs. $11.2M). The 10-K attributes this to increased property/equipment investment, likely including Endospan-related preparations and NEXUS manufacturing capacity buildout. If this is a temporary capex peak (the "J-curve" of investment before revenue), FCF should normalize to $25–35M by FY2027–2028 on the current EBITDA trajectory. If capex remains elevated, the FCF story is structurally impaired.

Operating CF is cleaner: $39.9M operating CF on $441M revenue = 9% OCF margin — acceptable for a growing med-tech. The OCF-to-net-income gap ($39.9M vs $9.8M GAAP net income) is primarily D&A and SBC addbacks, confirming reported earnings are heavily encumbered by non-cash charges.

---

4. Adversarial Research Sweep

Per the coverage-next-full path: analysis based on SEC filings, 8-K disclosures, press releases, and web search. No short-seller reports directly located. Key adversarial risks identified:

4.1 Cybersecurity Incident (Q4 2024)

Artivion disclosed a cybersecurity incident in November 2024 that disrupted ERP systems and operational capabilities. The company disclosed an estimated -$4.6M revenue impact in Q4 2024. The incident resulted in: operational disruptions to order processing and billing, possible data access by threat actors, and significant one-time remediation costs. The tissue preservation segment was disproportionately affected. [S1]

Assessment: The FY2025 recovery from this trough makes the YoY comparisons look better than the underlying trend. FY2026 will be the first truly clean comparison year. No evidence of ongoing compromise.

4.2 Italian Payback Mechanism

Italy requires medical device companies to rebate a portion of revenues exceeding government budget allocations. Artivion disclosed an estimated $2.3M liability for the 2019–2025 period — paid in 2025. Modest in magnitude but illustrates government pricing risk in European markets. [S1]

4.3 Endospan Acquisition Risk

The May 2026 Endospan acquisition re-leverages the balance sheet and concentrates manufacturing of the NEXUS product in a single Israeli facility. Risk factors include: geopolitical disruption to Israel-based operations, integration complexity, and the $200M in contingent payments (milestone-based) that could create significant future cash outflows if NEXUS achieves commercial success thresholds. [S1]

4.4 GLP-1 Secular Risk

Artivion management has acknowledged the long-term risk that GLP-1 drugs (Ozempic, Mounjaro) reducing obesity could decrease cardiovascular disease incidence over the next decade. The company argues its target patient population (complex aortic arch disease, genetic thoracic aortic aneurysms) is largely not obesity-driven — and therefore less exposed than coronary/valvular disease competitors. Judgment: plausible mitigant but warrants monitoring. [S1]

4.5 Short Interest / Activist Activity

• Juniper Investment Company (a 13D activist filer) sold approximately 234,000 shares during June–August 2025 at $29.62–$42.36, reducing its position — not a traditional short-seller attack but a significant institutional seller at elevated prices [S5]
• No prominent short-seller reports located targeting AORT specifically as of June 2026
• Oss Capital (~8.1% holder) is classified by some sources as activist-oriented; no public campaign as of research date [S3]

4.6 Financial Reporting Quality Assessment

PASS — No restatements, no material weaknesses disclosed, no qualified audit opinion. Reserves and estimates (goodwill, intangible amortization, tissue banking provisions) appear in line with industry norms. XBRL data is consistent with reported financials. Independent auditor: Ernst & Young LLP. [S1]

---

5. Source Index

• [S1] 10-K FY2025 — Artivion, Inc.
• [S2] XBRL company facts — xbrl/xbrl_summary.md
• [S3] Governance file — proxy/governance_and_compensation.md
• [S4] Consensus + guidance — other/consensus.md
• [S5] Insider transactions — proxy/insider_transactions.md

---

Thesis Tracker Update: Financial quality is adequate. Key risks: (1) capex elevation is temporary hypothesis needs monitoring; (2) Endospan re-leveraging is real and must be modeled; (3) SG&A ratio is high — leverage is key to EPS/FCF normalization. No fraud indicators found. Cybersecurity incident is resolved.

---

source: coverage-next-full step: 12 ticker: AORT company: Artivion, Inc. date: 2026-06-15

Step 12 — Bull/Bear Analyst Debate: Artivion, Inc. (AORT)

Note: Per the coverage-next-full path, no earnings call transcripts were loaded. The bull/bear debate below is inferred from: (1) SEC 10-K risk factors, (2) consensus analyst notes, (3) company press releases and 8-K filings, (4) investor presentation materials, and (5) industry competitive analysis. Transcript analysis was not performed.

---

1. The Debate in Brief

AORT is a stock where the market appears sharply divided: 7 covering analysts are unanimously bullish (6 Strong Buy, 1 Buy, avg. $42 target vs. ~$20 current). Yet the stock has lost ~50% from its late-2025 highs. The bear thesis is being expressed through selling, not through analyst coverage. Key contested issues:

1. NEXUS commercial ramp velocity — will it be slow (reimbursement friction, training curve) or fast (greenfield market, physician demand)?
2. Balance sheet after Endospan — value-creating acquisition or re-leverage trap?
3. Tariff headwinds permanence — temporary guide-down or structural margin degradation?
4. Preservation Services — stable-declining or accelerating decline?
5. Management's ability to generate FCF — when does the FCF story materialize?

---

2. Bull Case Argument

Bull Thesis: AORT is a first-mover in a greenfield $150M+ TAM with FDA-exclusive access to the arch EVAR market, backed by a diversified aortic platform with proven products and improving fundamentals — at a deep discount to intrinsic value.

Key bull evidence:

1. NEXUS is the only FDA-cleared branched arch EVAR device in the U.S. — 10–15 million patients with thoracic aortic disease in the U.S., with ~30,000+ arch procedures annually that previously required open surgery. If NEXUS captures even 20–30% of these within 3–5 years, it represents $30–45M in new U.S. revenue. [S3]

2. Consistent revenue beat track record — Artivion has beaten guidance every year since at least FY2020 (excluding the cybersecurity quarter). Q1 2026 is tracking at the high end of full-year guidance. [S4]

3. Medical Devices growing +19% with multiple product-level drivers — On-X is benefiting from PROACT Xa data; stent grafts have AMDS (domestic HDE) and NEXUS (global). This is not a single-product story. [S1]

4. Balance sheet cleaned up (then re-levered with a purpose) — The FY2025 delevering from ~3.4x to ~1.7x Net/EBITDA showed financial discipline. The Endospan re-levering is different: it buys a product with $150–600M TAM that is already FDA-approved. At 2.8–3.0x Debt/EBITDA, the balance sheet is manageable. [S1]

5. Adj. EBITDA margin expanding — From ~$74M (FY2023) to ~$90M (FY2025) on increasing revenue base. FY2026 guidance midpoint ($103.5M) implies 21.3% adj. EBITDA margin on midpoint revenue — first time crossing the 21% threshold. [S4]

6. Valuation is compelling — At ~$20/share and ~$1.0B market cap, AORT trades at ~2.1x EV/Revenue (based on ~$500M FY2026E) and ~10x FY2026E adj. EBITDA — a 45–50% discount to comparable med-tech M&A multiples and below its own historical EV/EBITDA range. Analyst consensus target of $42 implies doubling from current levels. [S4]

---

3. Bear Case Argument

Bear Thesis: AORT is a chronically ROIC-negative rollup that has diluted shareholders through serial acquisitions, generates no meaningful free cash flow, and is re-leveraging the balance sheet on a new-product launch (NEXUS) that faces significant adoption friction — all while reporting GAAP EPS of $0.21 on $441M revenue.

Key bear evidence:

1. NEXUS adoption risk is the critical unknown — New procedure categories in complex cardiac surgery historically ramp slowly. NEXUS requires: institutional credentialing, proctor-supervised initial cases, anesthesia team familiarity, reimbursement code establishment, and hospital C-suite buy-in. Competing open-surgery programs will resist losing cases. Adoption at $30M–$75M revenue in 3 years is far from certain. [S1]

2. Free cash flow is essentially zero — FY2025 FCF of $0.8M on $441M revenue (0.2% FCF margin) is not investible. Yes, capex spiked — but why did it spike, and will it normalize? If NEXUS/Endospan integration requires $30–40M capex annually for 3+ years, FCF generation is deferred to 2028 at the earliest. [S2]

3. Share count has grown 52% since 2016 — Every major acquisition added dilution. Endospan adds further equity (milestone shares). On a per-share basis, revenue growth has been near-zero in recent years. [S2]

4. SG&A at 51.3% of revenue is structurally high — For a company with $441M in revenue, SG&A of $226.5M represents an extremely bloated cost structure. Medtronic runs SG&A at ~30–33% of revenue. Even allowing for Artivion's niche clinical support requirements, there is no path to GAAP EPS of $1+ without either substantial SG&A reduction or revenue growth that the current cost base cannot easily service. [S1]

5. Tariff headwinds may be more persistent than guided — The FY2026 guidance cut was attributed to tariffs. If U.S. trade policy remains restrictive, the tariff cost headwind could compound. Artivion's international manufacturing (Israel, Germany) makes it more exposed than pure-U.S. manufacturers. [S4]

6. Preservation Services is declining with no bottom — Tissue banking declined 3% in FY2025 and is not a strategic priority. If decline accelerates to -5% to -10%, it offsets Medical Devices growth and strains company-level metrics. Artivion has not guided toward divestiture, but not divestiting a declining segment is also a capital allocation question. [S1]

---

4. Key Debate Points (Contested Assumptions)

Issue	Bull View	Bear View
NEXUS U.S. revenue (FY2027E)	$50–75M	$10–25M
Stent graft growth rate (FY2026–2027)	15–20% sustained	8–12% deceleration
FY2026 adj. EBITDA	$103M (guidance midpoint)	$95–100M (tariff miss)
Normalized annual capex	$15–20M (returns to historical)	$25–35M (Endospan integration)
FY2028 FCF	$35–55M	$10–25M
Post-deal Debt/EBITDA peak	2.8–3.0x (manageable)	3.5x+ (covenant risk in downside)

---

5. Bull Case — 3 Bullets

1. NEXUS FDA exclusivity creates a time-limited but real first-mover advantage in a $150M+ U.S. addressable market — no direct competitor, demonstrated clinical outcomes (TRIOMPHE trial), and surgical demand for an endovascular alternative to high-risk open arch surgery.

2. Revenue growth is multi-engine and accelerating — Medical Devices grew +19% in FY2025 with contributions from On-X (PROACT Xa tailwind), stent grafts (AMDS HDE + NEXUS), and geographic expansion; Q1 2026 +17.5% confirms momentum.

3. The stock trades at ~10x FY2026E adj. EBITDA and ~50% discount to analyst consensus — if execution holds and FCF normalizes by FY2027–2028, a re-rating to 15–18x EBITDA (peer-appropriate for a growing niche MedTech) implies substantial upside from current levels.

---

6. Bear Case — 3 Bullets

1. NEXUS commercial ramp is uncertain and faces structural friction — new procedure adoption in complex cardiac surgery is slow, reimbursement uncertainty is real, and larger competitors (Medtronic, Gore) are developing competing arch platforms with 5–7 year lag, not permanent exclusivity.

2. Free cash flow remains near-zero and the balance sheet is re-levered post-Endospan — at ~$295M net debt and ~$103M adj. EBITDA guidance, the company has limited financial flexibility; any revenue or capex miss tightens covenant headroom and delays the FCF normalization story.

3. SG&A at 51% of revenue and serial dilution since 2016 (+52% share count) mean per-share economics are structurally weak — GAAP EPS of $0.21 on $441M revenue is not a foundation for a sustainable valuation re-rating without a step-change in operating leverage.

---

7. Source Index

• [S1] 10-K FY2025 — Artivion, Inc.
• [S2] XBRL data + StockAnalysis.com
• [S3] Investor presentation + competitive landscape files
• [S4] Consensus file (other/consensus.md)

---

Thesis Tracker Update: The debate is concentrated on NEXUS adoption velocity and FCF normalization timing. These two variables dominate the range of outcomes. Bull case requires NEXUS to reach $50–75M U.S. revenue by FY2027 and capex to normalize to $15–20M/yr. Bear case assumes NEXUS underperforms and capex remains elevated. The market is currently pricing in the bear case (~50% stock de-rating from Dec 2025 highs).